...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Share transfer RBC
Reply New Message
Prev Message Back To Forum Threaded View Next Message

The new Managements estimate of fair value of common share is out on the Zenith website, letter is dated May 5, 2019 for a valuation of .725USD per share(.98CAD) as of Jan 31, 2019 

2 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply